CD28 and congenital rubella syndrome: A crucial issue with the polyclonal activation of T cells by TABs, independent of TAA binding, is a potentially fatal cytokine release syndrome (CRS) similar to the adverse events observed with a CD28 superagonist antibody (14, 31).